With this in mind we may assume that our finding of lower serum levels of sema4A in IBD patients (the precise explanation of which is not fully understood) is partially contributing to the failure of Treg cells in inhibiting CD4+ T cell pro-inflammatory responses. This evidence concerns the gene CD4 and inflammatory bowel disease.